

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津發展控股有限公司
TIANJIN DEVELOPMENT HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), an indirect non-wholly owned subsidiary of the Company, has published an announcement on the website of Shenzhen Stock Exchange (www.szse.cn) in respect of its indicative results for the first half of 2025, full text of which is reproduced in the attachment of this announcement.

As at the date of this announcement, the Company indirectly holds approximately 34.11% of the issued share capital of Lisheng Pharmaceutical.

By Order of the Board
Tianjin Development Holdings Limited
Teng Fei
Chairman and Executive Director

Hong Kong, 15 July 2025

As at the date of this announcement, the Board of the Company consists of Mr. Teng Fei, Dr. Zhai Xinxiang, Mr. Xia Binhui, Mr. Sun Lijun, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter**, Mr. Lau Ka Keung** and Mr. Sin Hendrick**.*

* *non-executive director*

** *independent non-executive director*

TIANJIN LISHENG PHARMACEUTICAL CO., LTD.**INDICATIVE RESULTS ANNOUNCEMENT
FOR THE FIRST HALF OF 2025**

The Company and all members of the board of directors warrant the truthfulness, accuracy and completeness of the contents of this announcement, and there are no false statements, misleading statements contained herein nor material omissions from this announcement.

I. INDICATIVE RESULTS FOR THE PERIOD

1. Period for the indicative results: 1 January 2025 to 30 June 2025
2. Indicative results: ☐ Loss ☐ Turnaround from loss ☒ Increase over the corresponding period last year ☐ Decrease over the corresponding period last year
3. Details of the indicative results

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the Company	Net profit: RMB 33000 to RMB 35500 (in ten thousand yuan)	Net profit: RMB 10235 (in ten thousand yuan)
	Increased by approximately 222.42% to 246.85% as compared to the corresponding period last year	
Net profit after deducting the extraordinary gains or losses	Net profit: RMB 10000 to RMB 11500 (in ten thousand yuan)	Net profit: RMB 9918 (in ten thousand yuan)
	Increased by approximately 0.83% to 15.95% as compared to the corresponding period last year	
Basic earnings per share	Earnings: RMB 1.28 per share to RMB 1.38 per share	Earnings: RMB 0.4 per share

II. COMMUNICATION WITH THE CERTIFIED PUBLIC ACCOUNTANTS

The relevant data related to the indicative results is based on the preliminary calculation made by the finance department of the Company and has not been audited by the certified public accountants. Regarding to the relevant matters related to the indicative results, the Company has communicated with the certified public accountants and there is no disagreement among us.

III. EXPLANATION FOR CHANGES IN RESULTS

The Company overcame product pricing challenges, actively explore market opportunities and expanded product sales, coupled with the dividend income from Tasly Group, the net profit attributable to shareholders of the Company have a higher year-on-year increase in the first half of 2025.

IV. OTHER RELEVANT INFORMATION

The data set out in the indicative results is based on the preliminary estimation by the finance department of the Company. The specific results data in details should be those disclosed in the Company's 2025 Interim Report. Investors are advised to exercise caution and pay attention to the investment risks involved.

The Board of Directors of
Tianjin Lisheng Pharmaceutical Co., Ltd.
15 July 2025